Pharmaceuticals APAC

APAC Pulmonary Fibrosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Pulmonary Fibrosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $999.7 Mn Placeholder estimate
Estimate 2025 $1.09 Bn 20.8% of the global market
Projected 2034 $2.43 Bn 122.6% Adds $1.34 Bn over 9 forecast years
CAGR 2025–2034 9.3% Faster than 48% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 20.82% of the global market.
  • Among regions, the largest is North America at $2.63 Bn.
  • Fastest growing: Africa at 9.5% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.34 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Pulmonary Fibrosis Treatment Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $999.7 Mn — —
2025 (base) $1.09 Bn +$93.0 Mn —
2026 (forecast) $1.19 Bn +$101.6 Mn +9.3%
2027 (forecast) $1.31 Bn +$111.1 Mn +19.5%
2028 (forecast) $1.43 Bn +$121.4 Mn +30.6%
2029 (forecast) $1.56 Bn +$132.7 Mn +42.7%
2030 (forecast) $1.70 Bn +$145.0 Mn +56%
2031 (forecast) $1.86 Bn +$158.5 Mn +70.5%
2032 (forecast) $2.04 Bn +$173.3 Mn +86.4%
2033 (forecast) $2.23 Bn +$189.4 Mn +103.7%
2034 (forecast) $2.43 Bn +$207.0 Mn +122.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Pulmonary Fibrosis Treatment Market Analysis at a glance
Market size, 2025$1.09 Bn placeholder estimate
Forecast, 2034$2.43 Bn placeholder estimate
Growth (CAGR), 2025–20349.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, type and end user (see all)
Key playersBoehringer Ingelheim GmbH, Roche, United Therapeutics, Bristol-Myers Squibb, Pliant Therapeutics (see all)
Active clinical trials89 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Pulmonary Fibrosis Treatment Market Analysis Executive Summary

Pulmonary fibrosis treatments slow scarring of the lungs, which makes breathing harder over time.

Key segments of the pulmonary Fibrosis Treatment market include drug (Nintedanib, Pirfenidone and Pipeline Therapies) and type (Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILD).

Bar chart: Asia Pacific Pulmonary Fibrosis Treatment market size, 2024–2034, placeholder estimates. $999.7 Mn in 2024, $1.09 Bn in 2025 and $2.43 Bn in 2034, 9.3% CAGR.
Asia Pacific Pulmonary Fibrosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Pulmonary Fibrosis Treatment Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the pulmonary Fibrosis Treatment market.

Opportunity

Earlier screening, new drug classes and home-based care give the pulmonary Fibrosis Treatment market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the pulmonary Fibrosis Treatment market.

Competitive Landscape for Pulmonary Fibrosis Treatment Market in APAC

The pulmonary Fibrosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pulmonary Fibrosis Treatment Market in APAC

Pulmonary Fibrosis Treatment in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], BPOM (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Drug Administration of Vietnam (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28]. ClinicalTrials.gov lists 89 studies on Pulmonary Fibrosis Treatment that are recruiting, active or about to start in APAC.⁠[29]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Drug Administration of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

[29] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pulmonary Fibrosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pulmonary Fibrosis Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pulmonary Fibrosis Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pulmonary Fibrosis Treatment market in Asia Pacific?
Placeholder estimate: about $1.09 Bn in 2025, rising to about $2.43 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pulmonary Fibrosis Treatment market in Asia Pacific growing?
Placeholder estimate: about 9.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pulmonary Fibrosis Treatment market report cover?
The report splits the market by drug (Nintedanib, Pirfenidone, Pipeline Therapies), type (Idiopathic Pulmonary Fibrosis, Progressive Fibrosing ILD) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Pulmonary Fibrosis Treatment market?
Key players include Boehringer Ingelheim GmbH, Roche, United Therapeutics, Bristol-Myers Squibb and Pliant Therapeutics.
What is driving the Pulmonary Fibrosis Treatment market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the pulmonary Fibrosis Treatment market.
How many clinical trials on Pulmonary Fibrosis Treatment are running in Asia Pacific?
89 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Pulmonary Fibrosis Treatment?
PubMed lists 81 papers on Pulmonary Fibrosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on respiratory

See the topic